<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764201</url>
  </required_header>
  <id_info>
    <org_study_id>HM-EDOX-101</org_study_id>
    <nct_id>NCT04764201</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open Label, Single Dose, 2-way Crossover Clinical Trial to Evaluate the Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic characteristics and safety&#xD;
      between HIP2001 and HGP2001 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2021</start_date>
  <completion_date type="Actual">March 8, 2021</completion_date>
  <primary_completion_date type="Actual">February 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>0~48 hours</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0~48 hours</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>0~48 hours</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0~48 hours</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>0~48 hours</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>0~48 hours</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>0~48 hours</time_frame>
    <description>Pharmacokinetic evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: HGP2001, Period 2: HIP2001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: HIP2001, Period 2: HGP2001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIP2001</intervention_name>
    <description>Test drug</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP2001</intervention_name>
    <description>Reference drug</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  19 kg/m^2 ≤ BMI &lt; 28 kg/m^2, weight &gt;60kg&#xD;
&#xD;
          -  90 mmHg ≤ SBP &lt;140 mmHg, 50 mmHg ≤ DBP &lt;900 mmHg&#xD;
&#xD;
          -  agrees that the person, spouse, or partner uses appropriate medically recognized&#xD;
             contraception and does not provide sperm or eggs from the date of administration of&#xD;
             the first investigational drug to 7 days after the administration of the last&#xD;
             investigational drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of hypersensitivity reactions or clinically significant hypersensitivity&#xD;
             reactions&#xD;
&#xD;
          -  A history of gastrointestinal diseases or surgery that may affect the absorption of&#xD;
             clinical trial drugs&#xD;
&#xD;
          -  A history of substance abuse or who test positive for drugs of concern for abuse in&#xD;
             the urine drug screening test&#xD;
&#xD;
          -  Positive results of serological tests&#xD;
&#xD;
          -  Have taken other investigational drugs or bioequivalence drugs within 6 months before&#xD;
             the first administration of the investigational drug&#xD;
&#xD;
          -  Donated whole blood within 60 days prior to the screening date or donated components&#xD;
             within 30 days or received a blood transfusion within 30 days&#xD;
&#xD;
          -  Have drank more than 210 g/week of alcohol within 30 days before the screening date&#xD;
&#xD;
          -  Have smoked more than 10 bills/day within 30 days before the screening date&#xD;
&#xD;
          -  AST, ALT value is more than 2 times the UNL or bilirubin level is more than 1.5 times&#xD;
             the UNL, eGFR &lt; 50 mL/min/1.73m2, Prothrombin (INR) &gt; 1.31 INR or aPTT &gt; 39.7 sec&#xD;
&#xD;
          -  12-ECG QTc &gt;450 ms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingeul Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeonbuk University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jeonbuk University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

